发明名称 |
Antibodies Against TL1a and Uses Thereof |
摘要 |
The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins. |
申请公布号 |
US2016333104(A1) |
申请公布日期 |
2016.11.17 |
申请号 |
US201615206493 |
申请日期 |
2016.07.11 |
申请人 |
Teva Pharmaceuticals Australia Pty Ltd |
发明人 |
Poulton Lynn Dorothy;Clarke Adam;Pow Andrew James;Tamvakis Debra;Kopsidas George;Doyle Anthony Gerard;Jennings Philip Anthony;Pollard Matthew |
分类号 |
C07K16/28 |
主分类号 |
C07K16/28 |
代理机构 |
|
代理人 |
|
主权项 |
1. A recombinant antibody that specifically binds to TL1a, comprising a variable heavy chain (VH) and a variable light chain (VL), wherein the VL comprises the following complementary determining regions (CDRs):
(i) a CDR1 comprising the sequence RASQSITNNLA comprising four or fewer amino acid substitutions; (ii) a CDR2 comprising the sequence DASTRAT comprising one or no amino acid substitution; and (iii) a CDR3 comprising the sequence QQYNNWPLT comprising three or fewer amino acid substitutions. |
地址 |
Macquarie Park AU |